XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	13	6	7	14	16	7
Market Cap Growth	-16.52%	-16.52%	-53.71%	-8.58%	121.17%	-20.81%
Enterprise Value	11	3	3	8	10	0
PE Ratio	-	-3.09	-4.89	32.74	-5.27	-9.23
PB Ratio	5.87	2.48	1.65	2.67	4.31	1.08
P/FCF Ratio	-7.79	-7.79	-7.32	-13.58	-18.31	-7.74
P/OCF Ratio	-7.79	-7.79	-7.32	-13.58	-18.33	-7.76
EV/EBITDA Ratio	-1.96	-1.96	-2.13	18.66	-3.23	-0.41
EV/EBIT Ratio	-1.96	-1.96	-2.13	18.66	-3.23	-0.41
EV/FCF Ratio	-4.95	-4.95	-3.19	-7.74	-11.21	-0.35
Return on Equity (ROE)	-57.30%	-57.30%	-28.90%	9.70%	-58.30%	-11.10%
Return on Assets (ROA)	-53.90%	-53.90%	-25.00%	6.60%	-43.10%	-9.70%
Return on Capital (ROIC)	-34.46%	-34.46%	-22.01%	-19.33%	-26.25%	-12.92%
Earnings Yield	-13.67%	-32.38%	-20.44%	3.05%	-18.96%	-10.83%
FCF Yield	-5.42%	-12.84%	-13.67%	-7.36%	-5.46%	-12.92%
Buyback Yield / Dilution	0.00%	0.00%	11.48%	-19.71%	-	-
Total Shareholder Return	0.00%	0.00%	11.48%	-19.71%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).